There is much research done and continuing to be done by many different organizations to try and understand the cause of Alzheimer’s Disease, and also how to reduce and relieve symptoms of it. Ongoing research is always being done in an effort to eradicate the disease altogether. According to the National Library of Medicine, Alzheimer’s Disease is considered to be the most common cause of dementia among the elderly population. The exact mechanism of AD has not yet been discovered, but it’s not for a lack of researchers trying.
Alzheimer’s Disease is recognized to have seven stages, ranging from mild cognitive impairment to severe dementia. This disease can last more than a decade, and tends to develop slowly and will worsen over the span of several years. Eventually, Alzheimer’s will affect most areas of the brain. Memory, thinking, judgment, language, and problem solving are just a few areas that are affected. There are also seven early signs of AD.
- Memory loss that affects daily life
- Loss of problem solving ability
- Limitations with language
- Misplacing things
- Poor judgment
- Personality changes
Early-Onset Alzheimer’s Disease
Alzheimer disease most commonly affects older adults, but it can also affect people in their 30s or 40s. When Alzheimer disease occurs in someone under age 65, it is known as early-onset (or younger-onset) Alzheimer disease.
A very small number of people with Alzheimer disease have the early-onset form. Many of them are in their 40s and 50s when the disease takes hold.
Hope For Alzheimer’s
Studies with Hyperbaric Oxygen Therapy are starting to show hope for those with Alzheimer’s. Below you will find a link to an article.
Alzheimers Treatment Hyperbaric Oxygen Therapy
Ongoing research suggests that Hyperbaric Oxygen Therapy is highly effective in this treatment. Physics World released an article that claimed that HBOT could “provide the means to slow progression, or prevent development of Alzheimer’s Disease”. Researchers have shown that hyperbaric therapy can improve cerebral blood flow and cognitive function in test mice, as well as in elderly patients with significant memory loss. Also demonstrated for the first time is that this treatment can reduce the volume of amyloid plaques ( clumps of protein) in these test mice. Being that amyloid plaques are a hallmark in the diagnosis of Alzheimer’s patients’ brains, this finding gives significant hope for similar results for those with the disease.
Additionally, it has been discovered that HBOT induces degradation and clearance of pre-existing amyloid plaque and in some cases actually stops the appearance of newly formed plaques by improving blood flow to the brain, reducing hypoxia. Research is showing improvement in cognitive ability such as spatial recognition memory, as well as contextual memory (the ability to remember emotional, social, spatial or temporal circumstances related to an event).